Kane Biotech Inc.
TSX VENTURE : KNE

Kane Biotech Inc.

November 09, 2005 09:03 ET

Kane Biotech Recieves Key U.S. Patent For The Treatment Of Dental Cavities

WINNIPEG, MANITOBA--(CCNMatthews - Nov. 9, 2005) - Kane Biotech Inc. (TSX VENTURE:KNE), a leading biofilm company, is pleased to announce the issuance of Patent No. 6,923,962 entitled "Signal Peptides, Nucleic Acid Molecules and Methods for Treatment of Caries", by the US Patent and Trademark Office. This patent protects the Company's CSP (Competence Stimulating Peptide) technology, a novel target for the development of improved oral care products. The issuance of this patent marks the Company's fifth U.S. patent.

"The granting of this patent meets an important milestone on Kane's path to developing successful products for the $70 billion US dental care market", stated Mr. Gord Froehlich, Vice President, Business Development for Kane Biotech. "Furthermore, Kane Biotech is committed to gaining worldwide protection for this technology in all other relevant jurisdictions."

"The discovery of CSP in Streptococcus mutans is an exciting one and the US Patent and Trademark Office has clearly recognized this unique technology with the issuance of this patent," commented Dr. Dennis Cvitkovitch, Associate Professor, Faculty of Dentistry, University of Toronto and the inventor of the technology. "It is both rewarding and encouraging to watch this technology move forward."

Streptococcus mutans, a bacterial strain present in virtually all humans, occurs as part of the normal flora in the mouth and tends to concentrate in the fissures, pits and crevices that are a typical part of teeth and gums. CSP has been shown to be responsible for many functions of Streptococcus mutans, including the regulation of biofilm formation (dental plaque), the ability to survive in acidic conditions, and the subsequent destruction of tooth enamel which results in dental cavities.

Kane Biotech continues to diligently pursue the technology covered in this patent, working towards the development of cavity and plaque preventing products. This includes the screening of peptide inhibitors that have been shown to prevent CSP from performing its essential role in plaque formation.

About Kane Biotech Inc.

Kane Biotech is a biotechnology company engaged in the development of products to prevent and disperse bacterial biofilms. Biofilms develop when bacteria, and other microorganisms, form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria become highly resistant to antibiotics, high temperatures and host immune responses. This resiliency contributes to human health problems such as recurrent urinary tract infections, medical device associated infections and tooth decay.

The Company recently announced commercial development of KBI-5898 for preventing device related urinary tract infections. KBI-5898 is a novel product that has shown in laboratory studies to be a broad spectrum anti-microbial, particularly effective against the most common pathogens implicated in urinary catheter related infections.


Certain information contained in this press release may be forward-looking and is subject to risks and uncertainties. Although the Company believes that the expectations contained herein are reasonable, it can give no assurances such forward-looking statements will prove correct. Information is provided from sources deemed to be reliable.

The TSX Venture Exchange has neither approved nor disapproved the contents of this press release.

Contact Information